Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug

Lonza Group said yesterday it signed a manufacturing agreement with Sweden’s Oasmia Pharma for ovarian cancer drug candidate Cantrixil that was licensed by Oasmia from the Australian pharma company Kazia last year.

Under the agreement, Lonza will provide kilogram-scale synthesis, purification and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply, the company said in a statement.

Manufacturing is expected to begin this month at Lonza’s recently expanded production facility at Nansha in China, the company said.